CNX Therapeutics to expand CNS portfolio through the acquisition of two established brands from Eisai

A pharmaceutical company has signed an agreement with a French sales subsidiary to buy two medicines for the treatment of mental health disorders and parkinsonian syndrome, which are linked to Parkinsons disease and neuroleptic-induced Parkinsonia Syndrome (PTSD) in the UK and Algeria. These products have been acquired by the French company Eisai. But (CSX Therapeutics - CMX Pharmaceuticals) says the acquisition of two drugs is expected to become the first major investment in Europe to expand its presence across the European market within the next two years. The announcement has been announced by British physicians and medical experts in France and Wales. A transition period has begun. It is to be completed by an international company based in Brussels, France, Germany and France. CSX therapeutic spending company CCX Tharmaceuticals Limited (Eisai) has confirmed that it has agreed to acquire two of the world s best-known therapies in its portfolio of psychiatric and neurological diseases and hospital emergencies between 2024 and the end of this year, as part of an ambitious deal aimed at improving the lives of patients suffering from psychological and mental illnesses and health issues including autism and Parkinsons, but further expands its ability to provide healthcare services to patients in more than 40 countries worldwide, and it is now ready to take part in an investment of 6.5m (4.5m) for developing their presences in European markets.

Source: pharmiweb.com
Published on 2024-04-03